Published in Cancer Weekly, February 16th, 1998
The results were presented at the 10th International Conference on Chemical Modifiers of Cancer Treatment, held in Clearwater, Florida, during January 1998.
RSR13 is a synthetic allosteric modifier of hemoglobin, a new class of pharmaceutical agents. RSR13 is a small molecule that reduces hemoglobin-oxygen binding affinity and increases oxygen delivery from blood to oxygen-deprived tissues. Allos is focusing on the clinical development of RSR13...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.